Melissa Fickey, MD’s Post

Medication isn’t the only route to relief. If your adolescent is experiencing depression, NeuroStar TMS is a safe and effective in-office treatment as an add-on therapy. NeuroStar uses magnetic pulses to stimulate mood-regulating areas in the brain for those with depression for ages 15 and older. In a clinical study of 1,169 adolescent patients: 78% cited improvement in their depression symptoms* 48% showed symptom relief (remission)* We’re here to help! Call our practice today to learn more about adding NeuroStar TMS to your loved one’s current treatment plan. Visit neurostar.com for full safety and prescribing information. *FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ± 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score ≤3 and “complete remission” was defined as a CGI-S score ≤2 at the end of treatment. #NeuroStarProvider #NeuroStarConnects #NeuroStar #NeuroStarSocial

Medication isn’t the only route to relief. If your adolescent is experiencing depression, NeuroStar TMS is a safe and effective in-office treatment as an add-on therapy. NeuroStar uses magnetic pulses to stimulate mood-regulating areas in the brain for those with depression for ages 15 and older. In a clinical study of 1,169 adolescent patients: 78% cited improvement in their depression symptoms* 48% showed symptom relief (remission)* Contact Totalinsight.ORG to learn more about adding NeuroStar TMS to your loved one’s current treatment plan. Visit neurostar.com for full safety and prescribing information. *FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ± 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score ≤3 and “complete remission” was defined as a CGI-S score ≤2 at the end of treatment. #NeuroStarProvider #TMS

Medication isn’t the only route to relief. If your adolescent is experiencing depression, Nurowav TMS is a safe and effective in-office treatment as an add-on therapy. Using NeuroStar technology, we send magnetic pulses to stimulate mood-regulating areas in the brain for those with depression for ages 15 and older. In a clinical study of 1,169 adolescent patients: 78% cited improvement in their depression symptoms* 48% showed symptom relief (remission)* Visit nurowavtms.com or call our practice today at 267-354-2894 for more information and to learn more about adding TMS to your loved one’s current treatment plan. *FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ± 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score ≤3 and “complete remission” was defined as a CGI-S score ≤2 at the end of treatment. #TMS #NeuroStarProvider #NeuroStar #adolescentdepression

An evaluation comparing TMS and ECT treatments indicated that TMS, specifically targeting the left DLPFC, achieved a higher remission rate with an 82% response rate. In contrast, ECT showed a response rate ranging from 75% to 83%. rTMS is a non-invasive therapy that does not require hospitalization, unlike ECT. It is favored for managing depression symptoms in patients with Major Depressive Disorder (MDD). For further insights into these treatment options, stay informed with Sebers Medical.

In our latest study published in Cell, the findings have revealed alarming trends in the burden of musculoskeletal (MSK) disorders among adolescents and young adults (AYAs) aged 15 to 39. The findings have significant implications for clinical practice and highlight the need for targeted interventions to prevent and manage early MSK disorders. • Implications for clinical practice: 1. Prioritize prevention and early management of MSK disorders in AYAs by implementing screening programs, providing targeted education on lifestyle modifications, and ensuring timely access to appropriate therapeutic interventions. 2. Address the social determinants of health and promote health equity by advocating for policies and programs that support healthy lifestyles and reduce the burden of early MSK disorders across all socioeconomic strata. 3. Collaborate with policymakers, public health officials, and community stakeholders to create environments that promote musculoskeletal health and prevent the development of early MSK disorders. As physicians, we must recognize the critical importance of focusing on MSK disorders in AYAs to establish lifelong patterns of health and reduce the disease burden in the era of an aging population. By implementing targeted interventions at the respective optimal ages and addressing the contributions of high BMI and kidney dysfunction, we can significantly impact the trajectory of MSK disorders and improve the quality of life for our patients. • The link to our study: https://lnkd.in/dPsSVMfG #MusculoskeletalHealth #MSKDisorders #AdolescentHealth #YoungAdultHealth #PreventiveMedicine #EarlyIntervention #HealthEquity #HealthDisparities #LifestyleModification #BodyMassIndex #KidneyDysfunction #LowBackPain #Osteoarthritis #Gout #NeckPain #SocialDeterminantsOfHealth #CollaborativeCare #PublicHealthPolicy #ClinicalPractice #PatientEducation #HealthPromotion #AgingPopulation #ChronicDiseasePrevention #MusculoskeletalResearch #CellJournal #GBDStudy

Why Compassion is Essential in Treating Orofacial Pain In the field of orofacial pain, compassion isn’t just an add-on—it’s a core component of effective care. Patients suffering from conditions like TMJ disorders, chronic jaw pain, and other orofacial issues often face more than just physical discomfort; they carry emotional and psychological burdens too. This is why a compassionate approach is so crucial. When patients come to us with chronic pain, they aren’t only seeking relief from physical symptoms—they are also looking for someone who understands the emotional toll of their condition. Chronic pain can be isolating, and many patients feel like no one truly gets what they are going through. That’s where compassion becomes invaluable. As healthcare providers, our role is not just to offer treatments but also to provide empathy and understanding. Compassion enables us to connect with patients on a deeper level, making them feel heard and supported. This emotional connection is just as vital as the clinical care we provide. When patients feel understood, it can help reduce anxiety and foster trust, ultimately improving their overall outcomes. Take TMJ disorder as an example. Many patients with this condition may feel embarrassed or frustrated by their symptoms, especially if they’ve faced misdiagnosis in the past. Compassionate care allows us to see them as individuals with unique struggles, rather than just a clinical case. It’s not only about relieving pain but about offering reassurance and building trust. A compassionate approach also strengthens the patient-provider relationship, leading to more open communication, better adherence to treatment plans, and more empowered patients on their healing journey. In orofacial pain care, we don’t just treat the symptoms—we address the whole person. And that starts with meeting our patients with understanding, patience, and compassion at every step. #orofacialpain #tmjdisorder #chronicpain #jawpain #tmjpain #migraine #migraines #painmanagement #healthcare #compassionatecare #patientcare #chronicpainawareness #healthcareproviders #noninvasivetreatments #oralhealth #tmjtherapy #painrelief #patientexperience #tmjcare #wellbeing

Cont. of the effects of Benzos: -There is no such thing as a “baby dose” of a benzo. 1 mg of Xanax = to 20 mg of Valium. 1 mg of Ativan = to 10 mg of Valium. “Baby dose” was a term pushed by the big pharma marketing against Valium dose, which Drs picked up. -According to Yale, 130M Americans are prescribed Benzos and studies show that 80-100% of people will experience benzo WD effects. 1 in 6 will suffer from BIND leaving them possibly disabled & fighting for their life. -Benzo WD & BIND sits on a LARGE spectrum: from anxiety, insomnia, panic attacks, itching, depression -TO- seizures, akathisia, hallucinations, occipital neuralgia, electrocutions, neuropathy, vertigo, hormone receptor damage, loss of mobility, pseudo dementia, POTS, “benzo belly”, lung suppression, agoraphobia, monophobia, DP/DR, mania, suicidal ideation, depression, PTSD, death, & 100’s more symptoms.  -“Kindling” is a phenomenon when a user discontinues their Benzo (or rapid taper) & then goes back onto a benzo. This increases odds of getting BIND. -Interdose intolerance often occurs during Benzo use. Which refers to Benzo WD symptoms in btw doses. Unfortunately, this is commonly misdiagnosed w/ other psychiatric illnesses & doctors tend to polydrug a patient. -Benzos use, interdose, WD & BIND can lead to suicide. -In the US we cannot open a class-act lawsuit against generic pharmaceutical companies, this came after a class-act lawsuit against Benozs in the UK -The gov has not done more on this matter due to pharmaceutical lobbyists, similar to the Opioid crisis.   -Drs NEED to continue prescribing Benzos to patients who are already on it, due to the dangers of cold-turkey & rapid taper.  -Due to benzo education, lawsuits are being made & won. There are EGG scans that show brain damage, expert psychiatrist witnesses & the FDA black boxed warning has helped win cases. Due to the lack of medical education- many are commonly misdiagnosed w/ one or multiple of the following: MS, ASL, Parkinson’s, Fibromyalgia, Trigeminal Neuralgia, Lupus, Lyme, Nerve Damage, Schizophrenia, Bipolar, Multiple Personality Disorder, Manic, etc. Benzos can mimic some to all of these illnesses at the same time. ALL people will heal from benzo WD and BIND, but no one can give a timeline. It can take months to several years. The brain needs time to heal from the synthetic damage. When I was first put on benzos I thought they were a miracle drug, like many, but soon enough they would be the thing trying to take my life. The protocols & help I got as a last resort were the things that actually helped me on all fronts, not the “medicine” that was pushed on me by very uneducated Drs. Please take back reverence. Do your own research when diagnosed or prescribed. Get a second or third opinion. See other types of Drs like Functional, Homeopathic or a Shamen. Benzo Information Coalition: Benzoinfo.com Benzo Support Resources: https://lnkd.in/ep4DCs4w Benzo Support Forum: Benzobuddies.org

YES. Transcranial Magnetic Stimulation (TMS) has demonstrated impressive efficacy in treating depression. Studies show a response rate of 49% and a remission rate of 32%.* TMS is a non-invasive, evidence-based treatment option that offers clinically significant antidepressant effects. It also boasts a favorable tolerability profile, making it a viable option for many patients. *in adult patients who have failed to achieve satisfactory improvement from two prior antidepressant medications, at or above the minimal effective dose and duration in the current episode (Blumberger, D.M., et al., 2018).

Evidence for Ketamine Infusion Therapy for PTSD, Major Depression, and Suicidal Ideation Ketamine infusion therapy has been studied for its rapid and significant effects on reducing symptoms of PTSD, major depression, and suicidal ideation. 1. Reduction in Suicidal Ideation: - Ketamine infusion significantly reduces suicidal ideation in patients with treatment-resistant depression and anxiety, with effects observed as soon as 40 minutes post-infusion and lasting up to several days! 2. Effects on Depression: - Repeated doses of ketamine have shown to improve depressive symptoms in patients with treatment-resistant depression, with sustained effects seen up to three months post-infusion! 3. Efficacy in Real-World Settings: - In real-world clinical settings, ketamine infusions have been effective in reducing both depressive symptoms and suicidal ideation, demonstrating feasibility and safety for broader application! 4. Impact on PTSD: - Significant improvements in PTSD symptoms, including reductions in intrusive thoughts, avoidance, and hyperarousal, have been observed following ketamine infusions in veterans with comorbid PTSD and depression! Ketamine infusion therapy is an effective and rapid intervention for reducing symptoms of major depression, PTSD, and suicidal ideation. Its rapid onset and sustained effects make it a promising treatment option, especially for treatment-resistant cases and acute suicidality! References Albott, C., Lim, K., Forbes, M., Thuras, P., Wels, J., Tye, S., & Shiroma, P. (2019). 3525 Improvement in Suicidal Ideation after Repeated Ketamine Infusions: Relationship to Reductions in Symptoms of Posttraumatic Stress Disorder, Depression, and Pain. Journal of Clinical and Translational Science, 3, 46 - 46. https://lnkd.in/gqSstqMi. McIntyre, R., Rodrigues, N., Lee, Y., Lipsitz, O., Subramaniapillai, M., Gill, H., Nasri, F., Majeed, A., Lui, L., Senyk, O., Phan, L., Carvalho, I., Siegel, A., Mansur, R., Brietzke, E., Kratiuk, K., Arekapudi, A., Abrishami, A., Chau, E., Szpejda, W., & Rosenblat, J. (2020). The effectivenesss of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.. Journal of affective disorders, 274, 903-910 . https://lnkd.in/gXB5bpYn. #ketamineinfusiontherapy #rapidactingtreatments #interventionalpsychiatry #ptsd #depression #mindfulhealthsolutions

Hallucinations and delusions, sometimes referred to as psychosis, occur in more than half of people with #Lewybodydementia (LBD). Currently, the only medication approved by the FDA to treat hallucinations and delusions in LBD is Nuplazid (pimavanserin). The US FDA in 2023 changed the prescribing label of pimavanserin to clarify that it can be used in #Parkinsons disease dementia (PDD; one of the two major forms of LBD), not just in Parkinson’s disease without dementia. In the HARMONY Study, 59 people with PDD were randomly assigned to receive either primavanserin or a placebo (sugar pill), and researchers followed them to see whether their #hallucinations or delusions relapsed. Although the sample size was small, the pimavanserin group had a 95% reduction in relapse compared to the placebo group. Learn more about the results of this study at https://ow.ly/ze2U50RzXkp